Malignant Solid Neoplasm — Trials

Malignant Solid Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 429
Recruiting: 209
Ph III recruiting: 10
Growth YoY: +2.3%
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: 29.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (101)

clinicaltrialsPublishedShowing 251–280 of 280 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04800627	Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor	terminated	Phase 1 / Phase 2	2	M.D. Anderson Cancer CenterOTHER	1	Dec 27, 2022	clinicaltrials
NCT05338957	A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.	unknown	Phase 1 / Phase 2	30	Shanghai Miracogen Inc.INDUSTRY	1	Dec 1, 2022	clinicaltrials